# US 2019/0375762 A1 · Mk2 inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375762 A1
- Document ID: US20190375762A1
- Status: Published application
- Kind: A1
- Application number: 16/375,317
- Filed: 2019-04-04
- Published: 2019-12-12
- Earliest claimed: 2014-09-17
- Assignees: Celgene CAR LLC
- Applicants: Celgene CAR LLC
- Inventors: Matthew David Alexander; Claudio Chuaqui; John Malona; Joseph John McDonald; Yike Ni; Deqiang Niu; Russell C. Petter; Juswinder Singh; Chittari Pabba
- Web page: https://patentgrep.com/patent/US20190375762A1

## CPC

- C07D 495/14: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

## Claims

### Claim at position 1

1-70. (canceled)

### Claim 71

A compound of the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 72 (depends on 71)

A pharmaceutical composition comprising the compound according to claim 71, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 73 (depends on 72)

The pharmaceutical composition according to claim 72, wherein said composition is formulated for parenteral administration.

### Claim 74 (depends on 72)

The pharmaceutical composition according to claim 72, wherein said compound is formulated for oral administration.
